A 1-42 stimulation markedly suppressed the activation of the bone morphogenetic protein 6 (BMP6)/SMAD1 signaling pathway in BV2 microglial cells, resulting in the downregulation of SLC7A11, GPX4, FTL1, and FTH1 expression, increased ROS and MDA levels, and decreased GSH and SOD levels
Furthermore, EGCG has been shown to inhibit microglial activation and reduce neuronal damage in SH-SY5Y and rat mesencephalic cultures (188)
BPC-157 has been studied for gastrointestinal and tendon injury applications
2 When developing alternative formulations (non-injectables and longacting analogs), challenges arise, such as low bioavailability of the analogs in blood and limited sample availability
This means looking at how the medication interacts with your body to cause these reactions
In various diseases, multiple sites are modified simultaneously [123]